Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30666
Title: A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis.
Austin Authors: Nguyenhuy, Minhtuan;Xu, Yifan;Maingard, Julian;Barnett, Stephen A ;Kok, Hong Kuan;Brooks, Mark;Jhamb, Ashu;Asadi, Hamed ;Knight, Simon R 
Affiliation: Department of Surgery, Peninsula Health, Frankston, VIC, 3199, Australia..
Department of Thoracic Surgery, Western Hospital, Footscray, Melbourne, VIC, 3011, Australia..
Radiology
Department of Vascular and Interventional Radiology, St Vincent's Hospital, Fiztroy, VIC, 3065, Australia..
Department of Interventional Radiology, Monash Health, Clayton, VIC, 3168, Australia..
Thoracic Surgery
Interventional Radiology Service, Northern Health Radiology, Epping, VIC, 3076, Australia..
Issue Date: Aug-2022
metadata.dc.date: 2022
Publication information: Cardiovascular and interventional radiology 2022; 45(8): 1102-1113
Abstract: Pulmonary metastasectomy has been widely adopted in the treatment of metastatic disease. In recent years image guided ablation has seen increased use in the treatment of thoracic malignancies. The objective of this study was to evaluate oncological outcomes following percutaneous ablation (PA) of pulmonary metastasis. A comprehensive search of the PubMed, MEDLINE and EMBASE databases from January 2000 to August 2021 was performed to identify studies evaluating patient survival following ablation of lung metastasis. Pooled outcomes have been presented with a random effects model to assess primary outcomes of overall survival, progression free survival and 1-year local control. Secondary outcomes included procedural mortality, major complications, and the incidence of pneumothorax. A total of 24 studies were identified. The pooled median overall survival was 5.13 [95% confidence interval (CI): 4.37-6.84] years, and the 1-, 3-, 5-year progression free survival rates were 53%, 26% and 20% respectively. The 1-year local control rate was 91% (95%CI: 86-95%). Periprocedural mortality was rare (0%; 95%CI: 0-1%), as were major complications excluding pneumothorax (1%; 95%CI: 1-2%). Pneumothorax developed in 44% of ablation sessions, although only half of these required chest tube placement. Most patients were able to be discharged day one post-procedurally. PA demonstrates high overall, progression free and local tumour survival in patients with lung metastasis. Complications and mortality are also rare. Consideration of its use should be made in a tumour board meeting in conjunction with surgical and radiotherapy perspectives for targeted local control of metastases.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30666
DOI: 10.1007/s00270-022-03116-z
ORCID: http://orcid.org/0000-0002-4546-2079
http://orcid.org/0000-0002-8350-2860
http://orcid.org/0000-0003-2475-9727
http://orcid.org/0000-0003-4837-9446
PubMed URL: 35355094
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35355094/
Type: Journal Article
Subjects: Ablation
Embolization
Lung
Oncology
Pulmonary
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.